Drug Profile
Research programme: obesity therapy - Humanetics
Alternative Names: S-100Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Humanetics Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA
- 21 Dec 2005 Preclinical trials in Obesity in USA (unspecified route)